LifeMD Q3 revenue misses analyst estimates, lowers FY outlook

Overview

• US virtual care provider's Q3 revenue fell 7% yr/yr, missing analyst expectations

• Company cites reduced marketing spend and slower partnership ramp-up for revenue decline

Outlook

• LifeMD sees Q4 revenue between $46 mln and $49 mln

• Company expects Q4 adjusted EBITDA loss of $4 mln to $2 mln

• LifeMD lowers 2026 revenue outlook to $188 mln-$191 mln from $205.5 mln-$212.5 mln

Result Drivers

• MARKETING SPEND REDUCTION - Co said deliberate cuts to marketing spend weighed on revenue but improved adjusted EBITDA

• PARTNERSHIP RAMP-UP - Slower-than-expected ramp-up of new partnerships contributed to lower revenue, per management

• PHARMACY SHIPMENT GROWTH - LifeMD Pharmacy shipment volume grew 58.3% yr/yr, supporting subscriber growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

• Wall Street's median 12-month price target for LifeMD Inc is $7.50, about 321.3% above its November 11 closing price of $1.78

Reuters Recommended Reads

• Nov 9 - Hims & Hers forecasts Q4 revenue below estimates as gross margin falls

• Nov 12 - Aveanna Healthcare beats Q3 revenue analyst estimates; raises forecast

• Nov 10 - Hims & Hers to offer peptides as soon as November after US eases curbs

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)